BY MARKETWIRE
-
Eli Lilly expands Zepbound options for patients without health insurance
The two highest doses of the weight loss drug Zepbound will now be available to US patients without health insurance.
-
Analyst calls Demant acquisition “big and sensible”
Elderly financial institution expert states Demant will certainly have a solid setting in the German market with the procurement.
-
Novo Nordisk to take important obesity hope to phase 3 trial
Novo Nordisk has actually made a decision to take subcutaneous and dental amycretin even more right into medical advancement.
-
BioNTech buys former vaccine rival
The purchase will certainly assist BioNTech technology with its significant financial investment in cancer cells therapy, records Bloomberg Information.
-
Bavarian Nordic initiates Phase 3 study with chikungunya vaccine in children
The business’s injection Vimkunya is currently accepted for usage in individuals aged 12 years or older in the United States, EU and UK.
-
Novo Nordisk signs license agreement with US biotech company
In overall, the United States firm will certainly be qualified to get as much as USD 812m in settlements along with possible nobilities for sale of any kind of items arising from t…
-
Analyst calls Demant acquisition “big and sensible”
Senior bank analyst says Demant will have a strong position in the German market with the acquisition.
-
Analyst: Novo Nordisk’s obesity hope could hit shelves as early as 2028
The Danish pharmaceutical firm has actually leapt directly to stage 3.
-
Novo Nordisk reclaims position as Europe’s most valuable company
According to a fresh summary, Novo Nordisk has a market capitalization of USD 359.28 bn, while SAP is close behind with USD 359bn.
-
Novo Nordisk to take important obesity hope to phase 3 trial
Novo Nordisk has actually made a decision to take subcutaneous and dental amycretin better right into professional advancement.
